Table 1.

Key clinical studies on LUT function in diabetic patients

Drug class	Compound	Study	Main finding	Reference
α1-Adrenoceptor antagonists	Tamsulosin	Observational study	0.7-point smaller reduction in IPSS in diabetic patients	Michel et al. 2000
	Alfuzosin, doxazosin, tamsulosin, terazosin	Retrospective analysis	IPSS reduction by 7.5 and 3.1 in diabetic and nondiabetic patients respectively	Bozlu et al. 2014
5α-reductase inhibitors	Dutasteride and finasteride	Population-based database analysis	Increased risk to develop new onset T2DM	Wei et al. 2019
Muscarinic receptor antagonists	Darifenacin	Observational study	Smaller improvement of urinary dysfunction in diabetic patients	Schneider et al. 2013
	α-Blocker + tolterodine	Observational study	Comparable IPSS improvement in diabetic and nondiabetic patients	Höfner et al. 2010
	α-Blocker + solifenacin	Case series	Smaller OAB symptom improvement in diabetic patients	Obata et al. 2013
	Solifenacin	Prospective open-label study	Comparable effect on diabetic OAB and idiopathic OAB	Choi et al. 2018
	Darifenacin or solifenacin vs. oxybutynin	Retrospective cohort study	Increased risk for developing diabetes in patients taking darifenacin or solifenacin	Selig et al. 2020